Ocriplasmin Completed Phase 3 Trials for Vitreomacular Adhesion Including Macular Hole Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01429441Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole